PeerVoice Oncology & Haematology Audio
by PeerVoice
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·147 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 14 epsHosts
Not detected.
Recent guests
Recent episodes
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Sep 4, 2026
Unknown duration
Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers
Aug 27, 2026
Unknown duration
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Aug 27, 2026
Unknown duration
Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes
Aug 14, 2026
Unknown duration
Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes
Aug 7, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 9/4/26 | Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers | Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers | — | ||||||
| 8/27/26 | Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers | Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers | — | ||||||
| 8/27/26 | Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes | Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes | — | ||||||
| 8/14/26 | Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes | Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes | — | ||||||
| 8/7/26 | Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes | Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes | — | ||||||
| 7/20/26 | Acute Hepatic PorphyriaClinical Presentations+3 | — | PeerVoiceOne Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings | — | Acute Hepatic Porphyriaclinical presentations+3 | — | 26m 33s | ||
| 6/9/26 | bladder cancermultidisciplinary team+3 | Andrea Necchi, MD | — | — | bladder cancerCME+3 | — | 21m 06s | ||
| 6/5/26 | TROP2-Directed ADCsAdvanced Breast Cancer+3 | Javier Cortés, MD, PhDLaura Huppert, MD | — | — | TROP2ADCs+3 | — | 19m 41s | ||
| 6/5/26 | Surgical InterventionsSystemic Innovations+3 | Silvia Stacchiotti, MDMichiel van de Sande, MD, PhD | PeerVoice | — | Tenosynovial Giant Cell Tumoursurgical interventions+3 | — | 18m 45s | ||
| 5/26/26 | head and neck cancerrecurrent cancer+3 | Trisha Wise-Draper, MD, PhD | — | — | head and neck cancerrecurrent cancer+3 | — | 54m 23s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/26/26 | refractory metastatic colorectal cancerpatient journey+3 | Marwan Fakih, MD | — | — | colorectal cancermetastatic cancer+3 | — | 28m 23s | ||
| 5/18/26 | Folate Receptor-AlphaGynecological Cancers+3 | Martin Köbel, MD | — | — | Folate Receptor-Alphagynecological cancers+3 | — | 29m 59s | ||
| 3/25/26 | Paroxysmal Nocturnal HaemoglobinuriaComplement Cascade+3 | Austin Kulasekararaj, MD, MRCP, FRCPath | — | — | Paroxysmal Nocturnal HaemoglobinuriaComplement Cascade+3 | — | 29m 29s | ||
| 3/25/26 | rare diseaseiMCD+4 | Pier Luigi Zinzani, MD, PhD | — | — | iMCDrare disease+3 | — | 20m 07s | ||
| 3/6/26 | SCLC treatmentimmunotherapy+3 | Jonathan W. Goldman, MDMisty Dawn Shields, MD, PhD | PeerVoice | — | SCLCimmunotherapy+3 | — | 40m 01s | ||
| 2/25/26 | VEXAS Syndromemedical education+3 | Matthew J. Koster, MD | — | — | VEXAS SyndromeMatthew J. Koster+4 | — | 28m 24s | ||
| 2/25/26 | HER2-Positive Metastatic Breast CancerFirst-Line Treatment+4 | Cristina Saura Manich, MD, PhD | — | — | HER2-PositiveMetastatic Breast Cancer+5 | — | 19m 34s | ||
| 1/7/26 | TROP2Triple-Negative Breast Cancer+3 | Rebecca Dent, MD, FRCP | TROP2-Targeted Antibody-Drug ConjugatesCanada | — | TROP2Triple-Negative Breast Cancer+3 | — | 21m 47s | ||
| 12/17/25 | Myelofibrosisp53 Dysregulation+3 | Francesco Passamonti, MD | — | — | Myelofibrosisp53+4 | — | 19m 41s | ||
| 12/17/25 | Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy | Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy | — | ||||||
| 11/8/25 | Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025 | Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025 | — | ||||||
| 10/30/25 | Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO | Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO | — | ||||||
| 10/30/25 | Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC | Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC | — | ||||||
| 10/8/25 | Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies | Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies | — | ||||||
| 10/3/25 | Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC | Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC | — | ||||||
Showing 25 of 159
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.